A pilot study to assess the safety and effectiveness of a novel injectable gene therapy (SB-001) for cats with chronic kidney disease-associated anemia that replaces the function of feline erythropoietin

Purpose

Evaluate the safety and effectiveness of SB-001 administered as a single intramuscular (IM) injection to 10 cats to treat anemia caused by chronic kidney disease.

Eligibility

Cats must undergo medical examination to assess the suitability, and fulfill the following criteria:

  • Be 2 years of age or older
  • Weigh 2.0 – 6.0 kg (4.4-13.2 pounds)
  • Have chronic kidney disease (IRIS stage 2 or higher with creatinine greater than or equal to 1.6 mg/dL)
  • Be anemic (PCV less than or equal to 22% with blood test parameters normochromic, normocytic and non-regenerative)
  • Have no other major illness that might affect the red blood cell count or reduce long term survival

For more information about this study and to inquire about eligibility and potential study benefits, please contact Dr. Allyson Berent or Jessica Mejia from the Interventional Radiology/Interventional Endoscopy Service at 212-329-8835 (jessica.mejia@amcny.org).

Back to top